G
Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
NSE:GLS
Price:
1 100.6
INR
-2.89%
Market Closed
Market Cap:
134.9B
INR
Income Statement
Earnings Waterfall
Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd
|
Revenue
|
22B
INR
|
|
Cost of Revenue
|
-9.9B
INR
|
|
Gross Profit
|
12.1B
INR
|
|
Operating Expenses
|
-6.6B
INR
|
|
Operating Income
|
5.5B
INR
|
|
Other Expenses
|
-1.3B
INR
|
|
Net Income
|
4.2B
INR
|
Income Statement
Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd
Currency: INR
Millions
TTM
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Revenue |
18 852
N/A
|
29 309
+55%
|
29 718
+1%
|
20 763
-30%
|
21 232
+2%
|
20 882
-2%
|
20 357
-3%
|
20 540
+1%
|
21 612
+5%
|
22 498
+4%
|
23 359
+4%
|
23 679
+1%
|
22 832
-4%
|
22 934
+0%
|
22 049
-4%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
(9 055)
|
(14 588)
|
(14 361)
|
(9 802)
|
(10 429)
|
(10 124)
|
(9 812)
|
(9 888)
|
(10 141)
|
(10 332)
|
(10 663)
|
(10 437)
|
(10 020)
|
(10 418)
|
(9 939)
|
|
| Gross Profit |
9 797
N/A
|
14 720
+50%
|
15 357
+4%
|
10 961
-29%
|
10 803
-1%
|
10 758
0%
|
10 546
-2%
|
10 651
+1%
|
11 471
+8%
|
12 166
+6%
|
12 695
+4%
|
13 242
+4%
|
12 812
-3%
|
12 516
-2%
|
12 110
-3%
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(4 176)
|
(6 394)
|
(6 620)
|
(4 792)
|
(5 011)
|
(4 920)
|
(4 868)
|
(4 960)
|
(5 427)
|
(5 514)
|
(5 941)
|
(6 308)
|
(6 591)
|
(6 663)
|
(6 604)
|
|
| Selling, General & Administrative |
(3 846)
|
(2 286)
|
(2 346)
|
(1 671)
|
(4 635)
|
(1 722)
|
(1 710)
|
(1 754)
|
(4 787)
|
(1 879)
|
(2 072)
|
(2 297)
|
(5 761)
|
(2 669)
|
(2 626)
|
|
| Depreciation & Amortization |
(334)
|
(507)
|
(520)
|
(367)
|
(379)
|
(388)
|
(391)
|
(401)
|
(421)
|
(448)
|
(480)
|
(504)
|
(535)
|
(552)
|
(572)
|
|
| Other Operating Expenses |
4
|
(3 602)
|
(3 754)
|
(2 753)
|
3
|
(2 809)
|
(2 767)
|
(2 804)
|
(218)
|
(3 187)
|
(3 389)
|
(3 506)
|
(296)
|
(3 442)
|
(3 406)
|
|
| Operating Income |
5 621
N/A
|
8 326
+48%
|
8 738
+5%
|
6 169
-29%
|
5 792
-6%
|
5 838
+1%
|
5 677
-3%
|
5 692
+0%
|
6 045
+6%
|
6 652
+10%
|
6 754
+2%
|
6 935
+3%
|
6 221
-10%
|
5 853
-6%
|
5 507
-6%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
(905)
|
(1 300)
|
(1 153)
|
(490)
|
(135)
|
(75)
|
(5)
|
(6)
|
283
|
(8)
|
(11)
|
(13)
|
99
|
(15)
|
(14)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(37)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
(6)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
|
| Total Other Income |
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
1
|
0
|
54
|
71
|
(0)
|
157
|
188
|
|
| Pre-Tax Income |
4 709
N/A
|
7 026
+49%
|
7 584
+8%
|
5 679
-25%
|
5 649
-1%
|
5 762
+2%
|
5 673
-2%
|
5 686
+0%
|
6 286
+11%
|
6 644
+6%
|
6 797
+2%
|
6 992
+3%
|
6 313
-10%
|
5 995
-5%
|
5 681
-5%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
(1 194)
|
(1 776)
|
(1 907)
|
(1 434)
|
(1 462)
|
(1 497)
|
(1 490)
|
(1 491)
|
(1 616)
|
(1 707)
|
(1 742)
|
(1 799)
|
(1 604)
|
(1 526)
|
(1 446)
|
|
| Income from Continuing Operations |
3 516
|
5 250
|
5 677
|
4 245
|
4 187
|
4 265
|
4 182
|
4 195
|
4 670
|
4 937
|
5 055
|
5 193
|
4 709
|
4 469
|
4 235
|
|
| Net Income (Common) |
3 516
N/A
|
5 250
+49%
|
5 677
+8%
|
4 245
-25%
|
4 187
-1%
|
4 265
+2%
|
4 182
-2%
|
4 195
+0%
|
4 670
+11%
|
4 937
+6%
|
5 055
+2%
|
5 193
+3%
|
4 709
-9%
|
4 469
-5%
|
4 235
-5%
|
|
| EPS (Diluted) |
28.69
N/A
|
48.69
+70%
|
48.39
-1%
|
35.4
-27%
|
35.63
+1%
|
34.79
-2%
|
34.12
-2%
|
34.24
+0%
|
38.11
+11%
|
40.29
+6%
|
41.26
+2%
|
42.28
+2%
|
38.38
-9%
|
36.41
-5%
|
34.43
-5%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
